Arrowhead Pharmaceuticals
(NASDAQ) ARWR
Arrowhead Pharmaceuticals Financials at a Glance
Market Cap
$10.56B
Revenue (TTM)
$622.01M
Net Income (TTM)
$300.91M
EPS (TTM)
$-2.15
P/E Ratio
-34.89
Dividend
$0.00
Beta (Volatility)
1.66 (High)
Dividend
$0.00
Beta (Volatility)
1.66 (High)
Price
$74.96
Volume
35,842
Open
$75.57
Price
$74.96
Volume
35,842
Open
$75.57
Previous Close
$74.96
Daily Range
$74.76 - $76.51
52-Week Range
$14.30 - $82.26
Dividend
$0.00
Beta (Volatility)
1.66 (High)
Price
$74.96
Volume
35,842
Open
$75.57
Previous Close
$74.96
Daily Range
$74.76 - $76.51
52-Week Range
$14.30 - $82.26
ARWR News
ARWR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Arrowhead Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
711
CEO
Christopher Richard Anzalone, PhD
Website
www.arrowheadpharma.comHeadquarters
Pasadena, CA 91105, US
ARWR Financials
Key Financial Metrics (TTM)
Gross Margin
100%
Operating Margin
-36%
Net Income Margin
-48%
Return on Equity
-46%
Return on Capital
-11%
Return on Assets
-13%
Earnings Yield
-2.87%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$10.56B
Shares Outstanding
140.86M
Volume
35.84K
Avg. Volume
2.08M
Financials (TTM)
Gross Profit
$829.45M
Operating Income
$98.35M
EBITDA
$164.82M
Operating Cash Flow
$179.55M
Capital Expenditure
$22.67M
Free Cash Flow
$156.89M
Cash & ST Invst.
$919.37M
Total Debt
$366.28M
Arrowhead Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$73.74M
-86.4%
Gross Profit
$73.74M
-86.4%
Gross Margin
100.00%
N/A
Market Cap
$10.56B
N/A
Market Cap/Employee
$17.34M
N/A
Employees
609
N/A
Net Income
$132.73M
-135.8%
EBITDA
$107.35M
-127.0%
Quarterly Fundamentals
Net Cash
$410.80M
+15.1%
Accounts Receivable
$15.69M
+563.2%
Inventory
$0.00
N/A
Long Term Debt
$1.33B
+98.2%
Short Term Debt
$47.77M
-33.4%
Return on Assets
-13.27%
N/A
Return on Invested Capital
-11.25%
N/A
Free Cash Flow
$81.88M
-82.0%
Operating Cash Flow
$84.44M
-81.6%